News & Updates
Filter by Specialty:
Depemokimab a safe remedy for severe asthma exacerbations
Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.
Depemokimab a safe remedy for severe asthma exacerbations
20 Sep 2024
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
The time of steroids as the treatment of choice for asthma and chronic obstructive pulmonary disease (COPD) exacerbations appears to be nearing its end with the arrival of a new monoclonal antibody therapy, according to the results of the ABRA study.
Benralizumab trumps steroids in treatment of asthma, COPD eosinophilic exacerbations
20 Sep 2024
Automated insulin pump system does not alter energy, nutrient intake in T1D patients
Use of the automated insulin delivery (AID) system delivers better glycaemic control in people with type 1 diabetes (T1D). However, switching to the Minimed 780G insulin pump system does not lead to notable changes in energy and nutrient intake in this population, according to a study.
Automated insulin pump system does not alter energy, nutrient intake in T1D patients
18 Sep 2024
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.